US5871472A
(en)
*
|
1987-11-17 |
1999-02-16 |
Brown University Research Foundation |
Planting devices for the focal release of neuroinhibitory compounds
|
US6515009B1
(en)
*
|
1991-09-27 |
2003-02-04 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US5811447A
(en)
*
|
1993-01-28 |
1998-09-22 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
IL100112A
(en)
*
|
1991-11-21 |
1996-01-31 |
Yeda Res & Dev |
Microdelivery device for enhanced drug administration to the eye
|
US5178635A
(en)
*
|
1992-05-04 |
1993-01-12 |
Allergan, Inc. |
Method for determining amount of medication in an implantable device
|
US5876438A
(en)
*
|
1993-08-02 |
1999-03-02 |
Houston Biotechnology Incorporated |
Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
|
US20030083733A1
(en)
*
|
1997-10-10 |
2003-05-01 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US20020091433A1
(en)
*
|
1995-04-19 |
2002-07-11 |
Ni Ding |
Drug release coated stent
|
US6099562A
(en)
*
|
1996-06-13 |
2000-08-08 |
Schneider (Usa) Inc. |
Drug coating with topcoat
|
US5837313A
(en)
*
|
1995-04-19 |
1998-11-17 |
Schneider (Usa) Inc |
Drug release stent coating process
|
US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
US20060280774A1
(en)
*
|
1995-06-02 |
2006-12-14 |
Allergan, Inc. |
Compositions and methods for treating glaucoma
|
US6107102A
(en)
*
|
1995-06-07 |
2000-08-22 |
Regents Of The University Of California |
Therapeutic microdevices and methods of making and using same
|
US5773019A
(en)
*
|
1995-09-27 |
1998-06-30 |
The University Of Kentucky Research Foundation |
Implantable controlled release device to deliver drugs directly to an internal portion of the body
|
US6299895B1
(en)
|
1997-03-24 |
2001-10-09 |
Neurotech S.A. |
Device and method for treating ophthalmic diseases
|
US5904144A
(en)
*
|
1996-03-22 |
1999-05-18 |
Cytotherapeutics, Inc. |
Method for treating ophthalmic diseases
|
US5928662A
(en)
*
|
1996-07-31 |
1999-07-27 |
Phillips; Andrew F. |
Ocular drug delivery device
|
NZ500018A
(en)
*
|
1997-03-31 |
2001-07-27 |
Alza Corp |
Diffusional implantable delivery system with capillary tube of cross-sectional area and length to deliver beneficial agent
|
US20040009924A1
(en)
*
|
1997-05-30 |
2004-01-15 |
Veronique Stoven |
Anticancer products for treating cystic fibrosis
|
CA2291659A1
(en)
*
|
1997-06-04 |
1998-12-10 |
Debio Recherche Pharmaceutique S.A. |
Implants for controlled release of pharmaceutically active principles and method for making same
|
US5902598A
(en)
*
|
1997-08-28 |
1999-05-11 |
Control Delivery Systems, Inc. |
Sustained release drug delivery devices
|
US6196993B1
(en)
|
1998-04-20 |
2001-03-06 |
Eyelab Group, Llc |
Ophthalmic insert and method for sustained release of medication to the eye
|
US6210639B1
(en)
|
1998-10-26 |
2001-04-03 |
Novartis Ag |
Apparatus, method and composition for cleaning and disinfecting
|
JP2002534370A
(en)
|
1998-12-30 |
2002-10-15 |
デクセル リミテッド |
Dispersible concentrate for delivering cyclosporin
|
EP1154691A4
(en)
*
|
1999-01-05 |
2004-07-07 |
Massachusetts Eye & Ear Infirm |
Targeted transscleral controlled release drug delivery to the retina and choroid
|
CA2360938C
(en)
*
|
1999-02-02 |
2008-01-08 |
Warren Oliver Haggard |
Controlled release composite
|
US20040121014A1
(en)
*
|
1999-03-22 |
2004-06-24 |
Control Delivery Systems, Inc. |
Method for treating and/or preventing retinal diseases with sustained release corticosteroids
|
US6217895B1
(en)
|
1999-03-22 |
2001-04-17 |
Control Delivery Systems |
Method for treating and/or preventing retinal diseases with sustained release corticosteroids
|
US6416777B1
(en)
*
|
1999-10-21 |
2002-07-09 |
Alcon Universal Ltd. |
Ophthalmic drug delivery device
|
DE60040876D1
(en)
|
1999-10-21 |
2009-01-02 |
Alcon Inc |
medication supply
|
ES2240180T3
(en)
|
1999-10-21 |
2005-10-16 |
Alcon Inc. |
SUB-TENON ADMINISTRATION OF MEDICINES.
|
US7943162B2
(en)
*
|
1999-10-21 |
2011-05-17 |
Alcon, Inc. |
Drug delivery device
|
AU774993B2
(en)
|
1999-12-28 |
2004-07-15 |
Kimberly-Clark Worldwide, Inc. |
Use-dependent indicator system for absorbent articles
|
JP2003527168A
(en)
|
1999-12-28 |
2003-09-16 |
キンバリー クラーク ワールドワイド インコーポレイテッド |
Controlled release antimicrobial wipes for hard surfaces
|
US7732404B2
(en)
*
|
1999-12-30 |
2010-06-08 |
Dexcel Ltd |
Pro-nanodispersion for the delivery of cyclosporin
|
US6852688B2
(en)
|
2000-03-10 |
2005-02-08 |
University Of Florida |
Compositions for treating diabetic retinopathy and methods of using same
|
US20040175410A1
(en)
*
|
2000-04-26 |
2004-09-09 |
Control Delivery Systems, Inc. |
Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
|
US20040115268A1
(en)
*
|
2000-04-26 |
2004-06-17 |
Control Delivery Systems, Inc. |
Systemic delivery of antiviral agents
|
US6375972B1
(en)
*
|
2000-04-26 |
2002-04-23 |
Control Delivery Systems, Inc. |
Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
|
US20040208910A1
(en)
*
|
2000-04-26 |
2004-10-21 |
Control Delivery Systems, Inc. |
Sustained release device and method for ocular delivery of adrenergic agents
|
US20050002986A1
(en)
*
|
2000-05-12 |
2005-01-06 |
Robert Falotico |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
US8236048B2
(en)
|
2000-05-12 |
2012-08-07 |
Cordis Corporation |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
US6726918B1
(en)
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
DE60135352D1
(en)
*
|
2000-08-30 |
2008-09-25 |
Univ Johns Hopkins |
DEVICE FOR INTRA-OCCULAR ACTIVE AGGREGATION
|
US9925087B2
(en)
*
|
2000-09-15 |
2018-03-27 |
Bruder Healthcare Company, Llc |
Wound and therapy compress and dressing
|
DE60124285T3
(en)
*
|
2000-09-29 |
2011-03-17 |
Cordis Corp., Miami Lakes |
COATED MEDICAL EQUIPMENT
|
CA2429998C
(en)
*
|
2000-11-29 |
2012-01-17 |
Oculex Pharmaceuticals, Inc. |
Intraocular implants for preventing transplant rejection in the eye
|
US6756049B2
(en)
*
|
2000-12-29 |
2004-06-29 |
Bausch & Lomb Incorporated |
Sustained release drug delivery devices
|
EP1847255A3
(en)
*
|
2001-01-03 |
2009-03-04 |
Bausch & Lomb Incorporated |
Sustained release drug delivery devices with coated drug cores
|
JP2004522730A
(en)
*
|
2001-01-03 |
2004-07-29 |
ボシュ・アンド・ロム・インコーポレイテッド |
Sustained release drug delivery device with coated drug core
|
CA2432203C
(en)
|
2001-01-03 |
2008-03-25 |
Michael J. Brubaker |
Sustained release drug delivery devices with multiple agents
|
JP2004521882A
(en)
*
|
2001-01-03 |
2004-07-22 |
ボシュ・アンド・ロム・インコーポレイテッド |
Sustained release drug delivery device with assembled permeable plug
|
JP2004520900A
(en)
*
|
2001-01-26 |
2004-07-15 |
ボシュ・アンド・ロム・インコーポレイテッド |
Improved manufacturing method of sustained release drug delivery device
|
US7181287B2
(en)
*
|
2001-02-13 |
2007-02-20 |
Second Sight Medical Products, Inc. |
Implantable drug delivery device
|
US6713081B2
(en)
*
|
2001-03-15 |
2004-03-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Ocular therapeutic agent delivery devices and methods for making and using such devices
|
US7431710B2
(en)
|
2002-04-08 |
2008-10-07 |
Glaukos Corporation |
Ocular implants with anchors and methods thereof
|
US6613083B2
(en)
*
|
2001-05-02 |
2003-09-02 |
Eckhard Alt |
Stent device and method
|
WO2002089767A1
(en)
|
2001-05-03 |
2002-11-14 |
Massachusetts Eye And Ear Infirmary |
Implantable drug delivery device and use thereof
|
ATE506929T1
(en)
|
2001-06-12 |
2011-05-15 |
Univ Johns Hopkins Med |
RESERVOIR DEVICE FOR INTRAOCULAR MEDICINAL DELIVERY
|
DE10133870A1
(en)
*
|
2001-07-12 |
2003-02-06 |
Chris P Lohmann |
Ophthalmic agent, use of EGF for the treatment of dry eye syndrome and insert for the administration of EGF to the eye
|
AU2002319606B2
(en)
*
|
2001-07-23 |
2006-09-14 |
Alcon, Inc. |
Ophthalmic drug delivery device
|
PT1409065E
(en)
|
2001-07-23 |
2007-03-30 |
Alcon Inc |
Ophthalmic drug delivery device
|
US20030158598A1
(en)
*
|
2001-09-17 |
2003-08-21 |
Control Delivery Systems, Inc. |
System for sustained-release delivery of anti-inflammatory agents from a coated medical device
|
JP2005509605A
(en)
|
2001-09-28 |
2005-04-14 |
マクニール−ピーピーシー・インコーポレイテッド |
A dosage form comprising an edible composition and an edible skin
|
US6982094B2
(en)
|
2001-09-28 |
2006-01-03 |
Mcneil-Ppc, Inc. |
Systems, methods and apparatuses for manufacturing dosage forms
|
US7122143B2
(en)
|
2001-09-28 |
2006-10-17 |
Mcneil-Ppc, Inc. |
Methods for manufacturing dosage forms
|
US6837696B2
(en)
|
2001-09-28 |
2005-01-04 |
Mcneil-Ppc, Inc. |
Apparatus for manufacturing dosage forms
|
US7838026B2
(en)
|
2001-09-28 |
2010-11-23 |
Mcneil-Ppc, Inc. |
Burst-release polymer composition and dosage forms comprising the same
|
US7217381B2
(en)
|
2001-09-28 |
2007-05-15 |
Mcneil-Ppc, Inc. |
Systems, methods and apparatuses for manufacturing dosage forms
|
US20060034929A1
(en)
*
|
2001-12-27 |
2006-02-16 |
Brubaker Michael J |
Sustained release drug delivery devices with prefabricated permeable plugs
|
US8685427B2
(en)
*
|
2002-07-31 |
2014-04-01 |
Boston Scientific Scimed, Inc. |
Controlled drug delivery
|
US8133501B2
(en)
|
2002-02-08 |
2012-03-13 |
Boston Scientific Scimed, Inc. |
Implantable or insertable medical devices for controlled drug delivery
|
WO2003071986A2
(en)
*
|
2002-02-22 |
2003-09-04 |
Control Delivery Systems, Inc. |
Method for treating otic disorders
|
KR101127502B1
(en)
*
|
2002-03-11 |
2012-03-23 |
알콘, 인코퍼레이티드 |
Implantable drug delivery system
|
WO2003092665A2
(en)
*
|
2002-05-02 |
2003-11-13 |
Massachusetts Eye And Ear Infirmary |
Ocular drug delivery systems and use thereof
|
US8871241B2
(en)
|
2002-05-07 |
2014-10-28 |
Psivida Us, Inc. |
Injectable sustained release delivery devices
|
BR0309844A
(en)
*
|
2002-05-07 |
2005-02-15 |
Control Delivery Sys Inc |
Processes for forming a drug delivery device
|
EP1509256B1
(en)
*
|
2002-05-24 |
2009-07-22 |
Angiotech International Ag |
Compositions and methods for coating medical implants
|
US8313760B2
(en)
*
|
2002-05-24 |
2012-11-20 |
Angiotech International Ag |
Compositions and methods for coating medical implants
|
US20030235610A1
(en)
*
|
2002-06-21 |
2003-12-25 |
Piedmont Pharmaceuticals, Llc |
Liposomes containing biologically active compounds
|
US6976584B2
(en)
*
|
2002-06-26 |
2005-12-20 |
Bausch & Lomb Incorporated |
Package for surgical implant
|
CN100435880C
(en)
*
|
2003-02-28 |
2008-11-26 |
微创医疗器械(上海)有限公司 |
Medicament elution interventional medical apparatus and preparing method thereof
|
DK1521573T3
(en)
*
|
2002-07-15 |
2008-03-25 |
Alcon Inc |
Non-polymeric, lipophilic, pharmaceutical implant compositions for intracellular use
|
US20070184089A1
(en)
*
|
2002-07-15 |
2007-08-09 |
Alcon, Inc. |
Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
|
US8920826B2
(en)
*
|
2002-07-31 |
2014-12-30 |
Boston Scientific Scimed, Inc. |
Medical imaging reference devices
|
DE10238310A1
(en)
*
|
2002-08-21 |
2004-03-04 |
Erich Jaeger Gmbh |
electrode assembly
|
EP1539065B1
(en)
|
2002-09-18 |
2012-12-12 |
Allergan, Inc. |
Apparatus for delivery of ocular implants
|
ES2428354T3
(en)
|
2002-09-18 |
2013-11-07 |
Trustees Of The University Of Pennsylvania |
Rapamycin for use in the inhibition or prevention of choroidal neovascularization
|
US20050203542A1
(en)
*
|
2002-09-18 |
2005-09-15 |
Allergan, Inc. |
Apparatus for delivery of ocular implants with reduced incidence of ocular adverse events
|
US6899717B2
(en)
*
|
2002-09-18 |
2005-05-31 |
Allergan, Inc. |
Methods and apparatus for delivery of ocular implants
|
US7807197B2
(en)
|
2002-09-28 |
2010-10-05 |
Mcneil-Ppc, Inc. |
Composite dosage forms having an inlaid portion
|
CA2498489C
(en)
*
|
2002-09-29 |
2010-02-23 |
Surmodics, Inc. |
Method for subretinal administration of therapeutics including steroids;method for localizing pharmacodynamic action at the choroid and the retina; and related methods for treatment and/or prevention of retinal diseases
|
WO2004036182A2
(en)
*
|
2002-10-17 |
2004-04-29 |
Control Delivery Systems, Inc. |
Methods for monitoring treatment of disease
|
AU2003287666A1
(en)
*
|
2002-11-13 |
2004-06-03 |
Control Delivery Systems, Inc. |
Systemic delivery of antiviral agents
|
JP2006523613A
(en)
|
2002-12-20 |
2006-10-19 |
エスティ.ジェイムス アソシエイト エルエルシー/フェイバー リサーチ シリーズ |
Coated particles for sustained release pharmaceutical administration
|
US20040137059A1
(en)
*
|
2003-01-09 |
2004-07-15 |
Thierry Nivaggioli |
Biodegradable ocular implant
|
US20050048099A1
(en)
*
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
KR20050123091A
(en)
*
|
2003-01-24 |
2005-12-29 |
컨트롤 딜리버리 시스템즈 인코포레이티드 |
Controlled release of highly soluble agents
|
AR042917A1
(en)
*
|
2003-01-24 |
2005-07-06 |
Control Delivery Sys Inc |
SUSTAINED RELEASE DEVICE FOR THE OCULAR ADMINISTRATION OF ADRENERGIC AGENTS AND USE OF ADRENERGIC AGENTS FOR THEIR PREPARATION
|
WO2004066980A2
(en)
*
|
2003-01-24 |
2004-08-12 |
Control Delivery Systems, Inc. |
Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
|
WO2004073551A2
(en)
*
|
2003-02-18 |
2004-09-02 |
Massachusetts Eye And Ear Infirmary |
Transscleral drug delivery device and related methods
|
EP1594511A2
(en)
*
|
2003-02-20 |
2005-11-16 |
Alcon, Inc. |
Formulations of glucocorticoids to treat pathologic ocular angiogenesis
|
ZA200505989B
(en)
*
|
2003-02-20 |
2006-12-27 |
Alcon Inc |
Use the steroids to treat ocular disorders
|
US20040166091A1
(en)
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
US9445901B2
(en)
*
|
2003-03-12 |
2016-09-20 |
Deger C. Tunc |
Prosthesis with sustained release analgesic
|
US7483750B2
(en)
*
|
2003-03-21 |
2009-01-27 |
Second Sight Medical Products, Inc. |
Transretinal implant and method of implantation
|
US20050261668A1
(en)
*
|
2003-03-28 |
2005-11-24 |
Bausch & Lomb Incorporated |
Drug delivery device
|
US7037521B2
(en)
*
|
2003-03-28 |
2006-05-02 |
Bausch & Lomb Incorporated |
Using a laser for cutting a hole in a capsule for controlled drug delivery
|
US8246974B2
(en)
*
|
2003-05-02 |
2012-08-21 |
Surmodics, Inc. |
Medical devices and methods for producing the same
|
ATE476960T1
(en)
*
|
2003-05-02 |
2010-08-15 |
Surmodics Inc |
SYSTEM FOR THE CONTROLLED RELEASE OF A BIOACTIVE INGREDIENT IN THE BACK OF THE EYE
|
US7589107B2
(en)
*
|
2003-05-19 |
2009-09-15 |
Othera Holding, Inc. |
Amelioration of vitrectomy-induced cataracts
|
KR20060019579A
(en)
*
|
2003-06-13 |
2006-03-03 |
알콘, 인코퍼레이티드 |
Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
|
ATE496056T1
(en)
|
2003-06-16 |
2011-02-15 |
Acad Of Science Czech Republic |
PYRIMIDINE COMPOUNDS WITH PHOSPHONATE GROUPS AS ANTIVIRAL NUCLEOTIDE ANALOGS
|
US20050048123A1
(en)
|
2003-06-26 |
2005-03-03 |
Control Delivery System, Inc. |
In situ gelling drug delivery system
|
AR047552A1
(en)
*
|
2003-06-26 |
2006-01-25 |
Control Delivery Sys Inc |
SUPPLY SYSTEMS OF BIODEGRADABLE SUSTAINED RELEASE PHARMACOS
|
CN1842321B
(en)
*
|
2003-06-26 |
2012-07-04 |
控制递送系统有限公司 |
Bioerodible sustained release drug delivery systems
|
US20040265356A1
(en)
*
|
2003-06-30 |
2004-12-30 |
Bausch & Lomb Incorporated |
Drug delivery device
|
US20050054586A1
(en)
*
|
2003-06-30 |
2005-03-10 |
Bartels Stephen P. |
Treatment of ophthalmic disorders
|
JP2007526019A
(en)
*
|
2003-07-10 |
2007-09-13 |
アルコン,インコーポレイティド |
Ophthalmic drug delivery device
|
ES2391975T3
(en)
*
|
2003-07-25 |
2012-12-03 |
Genvec, Inc. |
Adenoviral vector based vaccines
|
CN102144961A
(en)
*
|
2003-09-18 |
2011-08-10 |
参天制药株式会社 |
Transscleral delivery
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
US20050250737A1
(en)
*
|
2003-11-12 |
2005-11-10 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
US20070224278A1
(en)
*
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
US20050101582A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
SI1696822T1
(en)
*
|
2003-11-13 |
2010-07-30 |
Psivida Inc |
Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
|
EP1687032B1
(en)
|
2003-11-14 |
2010-02-24 |
Genvec, Inc. |
Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc).
|
CA2546042A1
(en)
|
2003-11-20 |
2005-06-09 |
Othera Pharmaceuticals, Inc. |
Amelioration of macular degeneration and other ophthalmic diseases
|
AU2004293463A1
(en)
*
|
2003-11-20 |
2005-06-09 |
Angiotech International Ag |
Implantable sensors and implantable pumps and anti-scarring agents
|
BRPI0405798B8
(en)
*
|
2003-11-28 |
2021-05-25 |
Halex Istar Ind Farmaceutica L |
process for eliminating alkaline residues present in 9-((1,3-dihydroxypropan-2-yloxy)methyl)-2-amino-1h-purin-6(9h)-one and pharmaceutical presentation
|
US20050136095A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Brian Levy |
Drug delivery device with suture ring
|
US7211272B2
(en)
*
|
2003-12-22 |
2007-05-01 |
Bausch & Lomb Incorporated |
Drug delivery device
|
US20050158365A1
(en)
|
2003-12-22 |
2005-07-21 |
David Watson |
Drug delivery device with mechanical locking mechanism
|
US20050137538A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Bausch & Lomb Incorporated |
Drug delivery device
|
BRPI0506983A
(en)
|
2004-01-20 |
2007-07-03 |
Allergan Inc |
localized eye therapy compositions, preferably comprising triamcinolone acetonide and hyaluronic acid
|
WO2005072703A2
(en)
*
|
2004-01-26 |
2005-08-11 |
Control Delivery Systems, Inc. |
Controlled and sustained delivery of nucleic acid-based therapeutic agents
|
US20060018949A1
(en)
*
|
2004-04-07 |
2006-01-26 |
Bausch & Lomb Incorporated |
Injectable biodegradable drug delivery system
|
AU2005243730B2
(en)
|
2004-04-12 |
2010-05-27 |
Genvec, Inc. |
Method of using adenoviral vectors to induce an immune response
|
BRPI0509901A
(en)
*
|
2004-04-13 |
2007-08-07 |
Alza Corp |
apparatus and method for transdermal delivery of fentanyl-based agents
|
US7691381B2
(en)
*
|
2004-04-15 |
2010-04-06 |
Allergan, Inc. |
Stabilized biodegradable neurotoxin implants
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US8147865B2
(en)
*
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20050244471A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US8512738B2
(en)
|
2004-04-30 |
2013-08-20 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase implants
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
US20050244463A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
US8685435B2
(en)
|
2004-04-30 |
2014-04-01 |
Allergan, Inc. |
Extended release biodegradable ocular implants
|
US20050244461A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Controlled release drug delivery systems and methods for treatment of an eye
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
US8673341B2
(en)
*
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US8119154B2
(en)
*
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US8425929B2
(en)
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
US20050244469A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
US20050244478A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Anti-excititoxic sustained release intraocular implants and related methods
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
US20050244462A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
US8455656B2
(en)
|
2004-04-30 |
2013-06-04 |
Allergan, Inc. |
Kinase inhibitors
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
US20060024350A1
(en)
*
|
2004-06-24 |
2006-02-02 |
Varner Signe E |
Biodegradable ocular devices, methods and systems
|
US8980930B2
(en)
|
2004-06-25 |
2015-03-17 |
The Johns Hopkins University |
Angiogenesis inhibitors
|
US20060110428A1
(en)
|
2004-07-02 |
2006-05-25 |
Eugene Dejuan |
Methods and devices for the treatment of ocular conditions
|
DE602004022523D1
(en)
*
|
2004-07-02 |
2009-09-24 |
Novagali Pharma Sa |
Use of emulsions for intra- and periocular injection
|
DK1765454T3
(en)
|
2004-07-02 |
2016-05-02 |
Mati Therapeutics Inc |
Device for submission of treatment medium to eye
|
WO2006017347A2
(en)
*
|
2004-07-12 |
2006-02-16 |
Allergan, Inc. |
Opthalmic compositions and methods for treating ophthalmic conditions
|
US20090214588A1
(en)
|
2004-07-16 |
2009-08-27 |
Nabel Gary J |
Vaccines against aids comprising cmv/r-nucleic acid constructs
|
US7117870B2
(en)
*
|
2004-07-26 |
2006-10-10 |
Clarity Corporation |
Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
|
US20060020253A1
(en)
*
|
2004-07-26 |
2006-01-26 |
Prescott Anthony D |
Implantable device having reservoir with controlled release of medication and method of manufacturing the same
|
CA2573892A1
(en)
*
|
2004-07-26 |
2006-02-09 |
Clarity Corporation |
Implantable device having reservoir with controlled release of medication and method of manufacturing the same
|
WO2006023130A2
(en)
*
|
2004-08-12 |
2006-03-02 |
Surmodics, Inc. |
Biodegradable controlled release bioactive agent delivery device
|
US20060045865A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Spherics, Inc. |
Controlled regional oral delivery
|
WO2006026504A2
(en)
*
|
2004-08-27 |
2006-03-09 |
Spherics, Inc. |
Mucoadhesive oral formulations of high permeability, high solubility drugs
|
CA2589602A1
(en)
*
|
2004-09-01 |
2006-04-13 |
Genvec, Inc. |
Adenoviral vectors able to transduce apcs, potential use in immune response generation
|
US20160106717A1
(en)
|
2004-09-24 |
2016-04-21 |
Gen Pharma Holdings LLC |
Cai-based systems and methods for the localized treatment of uveitis
|
CA2581126A1
(en)
|
2004-09-24 |
2006-04-06 |
Rfe Pharma Llc |
Carboxy-amido-triazoles for the localized treatment of ocular diseases
|
US20060067978A1
(en)
*
|
2004-09-29 |
2006-03-30 |
Bausch & Lomb Incorporated |
Process for preparing poly(vinyl alcohol) drug delivery devices
|
US20060068012A1
(en)
*
|
2004-09-29 |
2006-03-30 |
Bausch & Lomb Incorporated |
Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control
|
US20060067979A1
(en)
*
|
2004-09-30 |
2006-03-30 |
Bausch & Lomb Incorporated |
Ophthalmic drug release device for multiple drug release
|
US20060067980A1
(en)
*
|
2004-09-30 |
2006-03-30 |
Bausch & Lomb Incorporated |
Capsule for encasing tablets for surgical insertion into the human body
|
US20060078592A1
(en)
*
|
2004-10-12 |
2006-04-13 |
Bausch & Lomb Incorporated |
Drug delivery systems
|
US20070276481A1
(en)
*
|
2004-12-08 |
2007-11-29 |
Renner Steven B |
Drug delivery device
|
US20060134162A1
(en)
*
|
2004-12-16 |
2006-06-22 |
Larson Christopher W |
Methods for fabricating a drug delivery device
|
WO2006068898A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Bausch & Lomb Incorporated |
Reusable drug delivery device
|
JP2008525109A
(en)
*
|
2004-12-22 |
2008-07-17 |
アルコン,インコーポレイティド |
Eye drop administration device
|
US20060134175A1
(en)
*
|
2004-12-22 |
2006-06-22 |
Stephen Bartels |
Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
|
US20060134174A1
(en)
*
|
2004-12-22 |
2006-06-22 |
Bausch & Lomb Incorporated |
Pharmaceutical delivery system and method of use
|
US20060134176A1
(en)
*
|
2004-12-22 |
2006-06-22 |
Bausch & Lomb Incorporated |
Pharmaceutical delivery system and method of use
|
US8663639B2
(en)
*
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
WO2006086750A1
(en)
*
|
2005-02-09 |
2006-08-17 |
Macusight, Inc. |
Liquid formulations for treatment of diseases or conditions
|
AU2005100176A4
(en)
*
|
2005-03-01 |
2005-04-07 |
Gym Tv Pty Ltd |
Garbage bin clip
|
CN101180086A
(en)
*
|
2005-04-08 |
2008-05-14 |
苏尔莫迪克斯公司 |
Sustained release implants for subretinal delivery
|
WO2006127592A2
(en)
*
|
2005-05-26 |
2006-11-30 |
Othera Pharmaceuticals, Inc. |
Use of hydroxylamine derivates for inhibiting vitrectomy-induced cataracts
|
WO2007002184A1
(en)
*
|
2005-06-21 |
2007-01-04 |
Bausch & Lomb Incorporated |
Drug delivery device having zero or near zero-order release kinetics
|
US20060292202A1
(en)
*
|
2005-06-27 |
2006-12-28 |
Bausch & Lomb Incorporated |
Drug delivery device
|
EP1909812A4
(en)
|
2005-07-27 |
2009-11-25 |
Univ Florida |
Small compounds that correct protein misfolding and uses thereof
|
US8765146B2
(en)
*
|
2005-08-31 |
2014-07-01 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
US20070212397A1
(en)
*
|
2005-09-15 |
2007-09-13 |
Roth Daniel B |
Pharmaceutical delivery device and method for providing ocular treatment
|
DK1937244T3
(en)
|
2005-09-30 |
2018-10-29 |
Io Therapeutics Llc |
: CANCER TREATMENT WITH SPECIFIC RXR AGONISTS
|
US20070134244A1
(en)
*
|
2005-10-14 |
2007-06-14 |
Alcon, Inc. |
Combination treatment for pathologic ocular angiogenesis
|
NZ568694A
(en)
|
2005-11-09 |
2011-09-30 |
Zalicus Inc |
Method, compositions, and kits for the treatment of medical conditions
|
BRPI0618441B8
(en)
*
|
2005-11-10 |
2021-07-27 |
Genvec Inc |
adenoviral vector
|
US20070122449A1
(en)
*
|
2005-11-28 |
2007-05-31 |
Choonara Yahya E |
Biodegradable implantable drug delivery device
|
US20070178138A1
(en)
*
|
2006-02-01 |
2007-08-02 |
Allergan, Inc. |
Biodegradable non-opthalmic implants and related methods
|
JP5528708B2
(en)
|
2006-02-09 |
2014-06-25 |
参天製薬株式会社 |
Stable formulations and methods for preparing and using them
|
US20070203190A1
(en)
*
|
2006-02-22 |
2007-08-30 |
Ghanshyam Patil |
Hydroxylamines and derivatives for the inhibition of complement activation
|
US8222271B2
(en)
|
2006-03-23 |
2012-07-17 |
Santen Pharmaceutical Co., Ltd. |
Formulations and methods for vascular permeability-related diseases or conditions
|
US20110034498A1
(en)
*
|
2006-03-24 |
2011-02-10 |
Mcgovern Karen J |
Dosing regimens for the treatment of cancer
|
US20070232660A1
(en)
*
|
2006-04-04 |
2007-10-04 |
Allergan, Inc. |
Therapeutic and delivery methods of prostaglandin ep4 agonists
|
US7981096B2
(en)
*
|
2006-05-12 |
2011-07-19 |
David Castillejos |
Optic nerve head implant and medication delivery system
|
US8668676B2
(en)
*
|
2006-06-19 |
2014-03-11 |
Allergan, Inc. |
Apparatus and methods for implanting particulate ocular implants
|
US20070298073A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US8802128B2
(en)
*
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US9039761B2
(en)
|
2006-08-04 |
2015-05-26 |
Allergan, Inc. |
Ocular implant delivery assemblies with distal caps
|
CA2660151C
(en)
*
|
2006-08-07 |
2012-04-17 |
Bausch & Lomb Incorporated |
Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof
|
CA2661553A1
(en)
*
|
2006-08-23 |
2008-02-28 |
Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services |
Method of treating or preventing oxidative stress-related disease
|
SI2056799T1
(en)
*
|
2006-08-31 |
2013-11-29 |
Bausch & Lomb Incorporated |
Compositions and methods for treating or preventing glaucoma or progression thereof
|
WO2008027557A2
(en)
*
|
2006-08-31 |
2008-03-06 |
Spherics, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
JP2010502723A
(en)
*
|
2006-09-11 |
2010-01-28 |
ボーシュ アンド ローム インコーポレイティド |
Compositions and methods for treating, controlling, reducing, ameliorating or preventing allergies
|
US20110105559A1
(en)
*
|
2006-09-11 |
2011-05-05 |
Rohrs Brian R |
Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy
|
US20110104159A1
(en)
*
|
2006-09-11 |
2011-05-05 |
Rohrs Brian R |
Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
|
MX2009001711A
(en)
|
2006-11-17 |
2009-05-08 |
Supernus Pharmaceuticals Inc |
Sustained-release formulations of topiramate.
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
US20080145405A1
(en)
*
|
2006-12-15 |
2008-06-19 |
Kunzler Jay F |
Drug delivery devices
|
TWI433674B
(en)
|
2006-12-28 |
2014-04-11 |
Infinity Discovery Inc |
Cyclopamine analogs
|
CA2675022A1
(en)
*
|
2007-01-09 |
2008-07-17 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
UY30883A1
(en)
|
2007-01-31 |
2008-05-31 |
Alcon Res |
PUNCTURAL PLUGS AND METHODS OF RELEASE OF THERAPEUTIC AGENTS
|
US9220837B2
(en)
*
|
2007-03-19 |
2015-12-29 |
Insuline Medical Ltd. |
Method and device for drug delivery
|
WO2009081262A1
(en)
|
2007-12-18 |
2009-07-02 |
Insuline Medical Ltd. |
Drug delivery device with sensor for closed-loop operation
|
US20100286467A1
(en)
*
|
2007-03-19 |
2010-11-11 |
Benny Pesach |
Device for drug delivery and associated connections thereto
|
US8622991B2
(en)
*
|
2007-03-19 |
2014-01-07 |
Insuline Medical Ltd. |
Method and device for drug delivery
|
KR20090128499A
(en)
*
|
2007-03-19 |
2009-12-15 |
인슐린 메디컬 엘티디 |
Drug delivery device
|
US7911053B2
(en)
*
|
2007-04-19 |
2011-03-22 |
Marvell World Trade Ltd. |
Semiconductor packaging with internal wiring bus
|
US20080265343A1
(en)
*
|
2007-04-26 |
2008-10-30 |
International Business Machines Corporation |
Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
|
US20090042936A1
(en)
*
|
2007-08-10 |
2009-02-12 |
Ward Keith W |
Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
|
US20090062922A1
(en)
*
|
2007-09-05 |
2009-03-05 |
Mckay William F |
Method and apparatus for delivering treatment to a joint
|
US7910123B2
(en)
*
|
2007-09-05 |
2011-03-22 |
Warsaw Orthopedic |
Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent
|
WO2009035562A2
(en)
*
|
2007-09-07 |
2009-03-19 |
Qlt Plug Delivery, Inc |
Drug cores for sustained release of therapeutic agents
|
US20090087443A1
(en)
|
2007-09-27 |
2009-04-02 |
Bartels Stephen P |
Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery
|
TWI498136B
(en)
*
|
2007-10-09 |
2015-09-01 |
Alcon Res Ltd |
An injection device for delivering a rate and temperature-dependent substance into the eye and method of preparing the same
|
TWI451862B
(en)
*
|
2007-10-09 |
2014-09-11 |
Alcon Res Ltd |
Thermal coefficient driven drug pellet size for ophthalmic injection
|
EP2214608B1
(en)
*
|
2007-11-08 |
2015-03-04 |
Alimera Sciences, Inc. |
Ocular implantation device
|
GB0722484D0
(en)
*
|
2007-11-15 |
2007-12-27 |
Ucl Business Plc |
Solid compositions
|
US20100297118A1
(en)
*
|
2007-12-27 |
2010-11-25 |
Macdougall John |
Therapeutic Cancer Treatments
|
WO2009086451A1
(en)
|
2007-12-27 |
2009-07-09 |
Infinity Pharmaceuticals, Inc. |
Methods for stereoselective reduction
|
AU2008345151A1
(en)
*
|
2007-12-27 |
2009-07-09 |
Infinity Pharmaceuticals, Inc. |
Therapeutic cancer treatments
|
TWI444384B
(en)
|
2008-02-20 |
2014-07-11 |
Gilead Sciences Inc |
Nucleotide analogues and their use in the treatment of malignancies
|
CA2716185C
(en)
|
2008-02-21 |
2017-03-21 |
Rutgers, The State University Of New Jersey |
Compositions and methods for treating ophthalmic diseases
|
US20100152646A1
(en)
*
|
2008-02-29 |
2010-06-17 |
Reshma Girijavallabhan |
Intravitreal injection device and method
|
WO2009140246A2
(en)
|
2008-05-12 |
2009-11-19 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US10064819B2
(en)
|
2008-05-12 |
2018-09-04 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US9095404B2
(en)
|
2008-05-12 |
2015-08-04 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US9877973B2
(en)
|
2008-05-12 |
2018-01-30 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US20090291073A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Ward Keith W |
Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
|
EP2334686B1
(en)
|
2008-08-28 |
2019-02-27 |
President and Fellows of Harvard College |
Cortistatin analogues and syntheses therof
|
US7985208B2
(en)
*
|
2008-09-18 |
2011-07-26 |
Oasis Research LLC |
Ring shaped contoured collagen shield for ophthalmic drug delivery
|
CN102245137A
(en)
|
2008-11-07 |
2011-11-16 |
茵苏莱恩医药有限公司 |
Device and method for drug delivery
|
US20100158980A1
(en)
*
|
2008-12-18 |
2010-06-24 |
Casey Kopczynski |
Drug delivery devices for delivery of therapeutic agents
|
US8545554B2
(en)
*
|
2009-01-16 |
2013-10-01 |
Allergan, Inc. |
Intraocular injector
|
CA2757037C
(en)
|
2009-01-29 |
2019-08-06 |
Forsight Vision4, Inc. |
Posterior segment drug delivery
|
US8623395B2
(en)
|
2010-01-29 |
2014-01-07 |
Forsight Vision4, Inc. |
Implantable therapeutic device
|
US9636255B2
(en)
|
2009-02-13 |
2017-05-02 |
Dose Medical Corporation |
Uveoscleral drug delivery implant and methods for implanting the same
|
WO2010096561A1
(en)
|
2009-02-18 |
2010-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic hiv/siv gag proteins and uses thereof
|
US20110077270A1
(en)
*
|
2009-04-21 |
2011-03-31 |
Pfeffer Bruce A |
Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
|
US8632511B2
(en)
*
|
2009-05-06 |
2014-01-21 |
Alcon Research, Ltd. |
Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
|
WO2010135369A1
(en)
*
|
2009-05-18 |
2010-11-25 |
Dose Medical Corporation |
Drug eluting ocular implant
|
US10206813B2
(en)
|
2009-05-18 |
2019-02-19 |
Dose Medical Corporation |
Implants with controlled drug delivery features and methods of using same
|
JP5695035B2
(en)
|
2009-06-03 |
2015-04-01 |
フォーサイト・ビジョン5・インコーポレイテッドForsight Vision5,Inc. |
Anterior eye drug supply
|
GB201111485D0
(en)
|
2011-07-05 |
2011-08-17 |
Biocopea Ltd |
Drug composition and its use in therapy
|
IN2012DN00352A
(en)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
JP6141015B2
(en)
|
2009-08-05 |
2017-06-07 |
インフィニティ ファーマスーティカルズ、インク. |
Enzymatic transamination of cyclopamine analogues.
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
WO2011047316A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
EP2498783B1
(en)
|
2009-11-09 |
2018-08-22 |
Allergan, Inc. |
Compositions and methods for stimulating hair growth
|
AU2010319398B2
(en)
|
2009-11-13 |
2014-06-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
|
US8177747B2
(en)
*
|
2009-12-22 |
2012-05-15 |
Alcon Research, Ltd. |
Method and apparatus for drug delivery
|
CN102740830A
(en)
*
|
2009-12-23 |
2012-10-17 |
普西维达公司 |
Sustained release delivery devices
|
US20110183948A1
(en)
*
|
2010-01-15 |
2011-07-28 |
Infinity Pharmaceuticals, Inc. |
Treatment of fibrotic conditions using hedgehog inhibitors
|
US10166142B2
(en)
|
2010-01-29 |
2019-01-01 |
Forsight Vision4, Inc. |
Small molecule delivery with implantable therapeutic device
|
US20110189174A1
(en)
*
|
2010-02-01 |
2011-08-04 |
Afshin Shafiee |
Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
|
EP2533737B1
(en)
|
2010-02-08 |
2014-01-08 |
On Demand Therapeutics, Inc. |
Low-permeability, laser-activated drug delivery device
|
WO2011112623A1
(en)
|
2010-03-08 |
2011-09-15 |
Spectrum Pharmaceuticals, Inc. |
Thioxanthone-based autophagy inhibitor therapies to treat cancer
|
US9682133B2
(en)
|
2010-03-17 |
2017-06-20 |
Cornell University |
Disrupted adenovirus-based vaccine against drugs of abuse
|
EP2547660B1
(en)
|
2010-03-19 |
2015-01-07 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Nitroxyl (hno) releasing compounds and uses thereof in treating diseases
|
EP2383286A1
(en)
|
2010-04-30 |
2011-11-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of retinal degenerative diseases
|
WO2011146483A1
(en)
|
2010-05-17 |
2011-11-24 |
Aerie Pharmaceuticals, Inc. |
Drug delivery devices for delivery of ocular therapeutic agents
|
WO2011159824A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
Composition and method for treating overactive bladder
|
AU2011285548B2
(en)
|
2010-08-05 |
2014-02-06 |
Forsight Vision4, Inc. |
Combined drug delivery methods and apparatus
|
RS62540B1
(en)
|
2010-08-05 |
2021-12-31 |
Forsight Vision4 Inc |
Apparatus to treat an eye
|
RS61601B1
(en)
|
2010-08-05 |
2021-04-29 |
Forsight Vision4 Inc |
Injector apparatus for drug delivery
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
US8697057B2
(en)
|
2010-08-19 |
2014-04-15 |
Allergan, Inc. |
Compositions and soft tissue replacement methods
|
WO2012024072A1
(en)
|
2010-08-19 |
2012-02-23 |
Allergan, Inc. |
Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
|
US8821457B2
(en)
*
|
2010-09-08 |
2014-09-02 |
Johnson & Johnson Vision Care, Inc. |
Punctal plug containing drug formulation
|
US9394313B2
(en)
|
2010-09-14 |
2016-07-19 |
Infinity Pharmaceuticals, Inc. |
Transfer hydrogenation of cyclopamine analogs
|
AU2011329656B2
(en)
|
2010-11-19 |
2017-01-05 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
US9668915B2
(en)
|
2010-11-24 |
2017-06-06 |
Dose Medical Corporation |
Drug eluting ocular implant
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
EP2654786B1
(en)
|
2010-12-20 |
2019-02-20 |
GenVec, Inc. |
Adenoviral vector-based dengue fever vaccine
|
US20120238994A1
(en)
*
|
2010-12-22 |
2012-09-20 |
Martin Nazzaro |
Two-piece injectable drug delivery device with heat-cured seal
|
CA2827615A1
(en)
|
2011-02-17 |
2012-08-23 |
Dennis E. Van Epps |
Compositions and improved soft tissue replacement methods
|
EP2678022A2
(en)
|
2011-02-23 |
2014-01-01 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
US9012647B2
(en)
|
2011-04-07 |
2015-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders
|
US8889672B2
(en)
|
2011-04-29 |
2014-11-18 |
The Regents Of The University Of Michigan |
Compounds, formulations, and methods of protein kinase C inhibition
|
SG194843A1
(en)
|
2011-05-18 |
2013-12-30 |
Univ California |
Compositions and methods for treating retinal diseases
|
WO2012162428A1
(en)
|
2011-05-23 |
2012-11-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Prime-boost vaccination for viral infection
|
CN105853445A
(en)
*
|
2011-06-06 |
2016-08-17 |
橡冠科学研究院 |
Drug delivery device employing wicking release window
|
US20120316199A1
(en)
|
2011-06-07 |
2012-12-13 |
Ward Keith W |
Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
|
US10245178B1
(en)
|
2011-06-07 |
2019-04-02 |
Glaukos Corporation |
Anterior chamber drug-eluting ocular implant
|
US9133082B2
(en)
|
2011-06-14 |
2015-09-15 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
EP2726016B1
(en)
|
2011-06-28 |
2023-07-19 |
ForSight Vision4, Inc. |
An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
|
WO2013023115A1
(en)
|
2011-08-10 |
2013-02-14 |
On Demand Therapeutics, Inc. |
Laser-activated drug delivery device
|
US9102105B2
(en)
|
2011-09-13 |
2015-08-11 |
Vista Scientific Llc |
Method for forming an ocular drug delivery device
|
WO2013040426A2
(en)
*
|
2011-09-14 |
2013-03-21 |
Forsight Labs, Llc |
Ocular insert apparatus and methods
|
WO2013040247A2
(en)
|
2011-09-16 |
2013-03-21 |
Forsight Vision4, Inc. |
Fluid exchange apparatus and methods
|
US8685106B2
(en)
|
2011-11-15 |
2014-04-01 |
Abraham Lin |
Method of a pharmaceutical delivery system for use within a joint replacement
|
JP6126118B2
(en)
|
2011-11-30 |
2017-05-10 |
ビカム ファーマスーティカルス,インコーポレイテッド |
Opsin binding ligands, compositions and methods of use
|
WO2013081642A1
(en)
|
2011-12-01 |
2013-06-06 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
US10653650B2
(en)
|
2011-12-13 |
2020-05-19 |
Io Therapeutics, Inc. |
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
|
US20130190395A1
(en)
|
2011-12-13 |
2013-07-25 |
Dartmouth College |
Autoimmune disorder treatment using rxr agonists
|
US9364316B1
(en)
*
|
2012-01-24 |
2016-06-14 |
Clarvista Medical, Inc. |
Modular intraocular lens designs, tools and methods
|
US10080648B2
(en)
|
2012-01-24 |
2018-09-25 |
Clarvista Medical, Inc. |
Modular intraocular lens designs, tools and methods
|
US10028824B2
(en)
|
2012-01-24 |
2018-07-24 |
Clarvista Medical, Inc. |
Modular intraocular lens designs, tools and methods
|
EP2806828B1
(en)
|
2012-01-24 |
2021-07-21 |
The Regents of The University of Colorado, A Body Corporate |
Modular intraocular lens designs and methods
|
WO2013116061A1
(en)
|
2012-02-03 |
2013-08-08 |
Forsight Vision4, Inc. |
Insertion and removal methods and apparatus for therapeutic devices
|
EP2811952A1
(en)
|
2012-02-07 |
2014-12-17 |
On Demand Therapeutics, Inc. |
Drug delivery devices and methods of use thereof
|
WO2013123275A1
(en)
|
2012-02-16 |
2013-08-22 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
WO2013123270A1
(en)
|
2012-02-16 |
2013-08-22 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
WO2013123274A1
(en)
|
2012-02-16 |
2013-08-22 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
WO2013123272A1
(en)
|
2012-02-16 |
2013-08-22 |
Allergan, Inc. |
Compositions and improved soft tissue replacement methods
|
WO2013124477A1
(en)
|
2012-02-24 |
2013-08-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of retinal degenerative diseases
|
US10093947B2
(en)
|
2012-02-28 |
2018-10-09 |
Cornell University |
AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
|
WO2013154744A1
(en)
|
2012-04-13 |
2013-10-17 |
Cornell University |
Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
|
WO2013180967A1
(en)
|
2012-05-29 |
2013-12-05 |
Genvec, Inc. |
Herpes simplex virus vaccine
|
US9827401B2
(en)
|
2012-06-01 |
2017-11-28 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
JP6549482B2
(en)
|
2012-06-01 |
2019-07-24 |
サーモディクス,インコーポレイテッド |
Device and method for coating a balloon catheter
|
EP2900270B1
(en)
|
2012-09-26 |
2019-03-06 |
Tangent Reprofiling Limited |
Combination of benzo(iso)oxazolepiperidines with conjugated linoleic acid
|
US20140100249A1
(en)
|
2012-10-09 |
2014-04-10 |
Douglas Sears |
Therapeutic Treatment
|
CN104869989A
(en)
|
2012-10-24 |
2015-08-26 |
比奥科普有限公司 |
Drug combinations and uses
|
US11090468B2
(en)
|
2012-10-25 |
2021-08-17 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
WO2014066775A1
(en)
|
2012-10-26 |
2014-05-01 |
Forsight Vision5, Inc. |
Ophthalmic system for sustained release of drug to eye
|
WO2014093270A1
(en)
|
2012-12-10 |
2014-06-19 |
Virginia Commonwealth University |
Tropism modified cancer terminator virus (ad.5/3 ctv;ad.5/3-ctv-m7)
|
WO2014108571A2
(en)
|
2013-01-14 |
2014-07-17 |
Biocopea Limited |
Cancer drug and uses
|
CA2901280A1
(en)
|
2013-02-15 |
2014-08-21 |
Allergan, Inc. |
Sustained drug delivery implant
|
EP2968613B1
(en)
|
2013-03-11 |
2019-09-11 |
University of Florida Research Foundation, Inc. |
Delivery of card protein as therapy for occular inflammation
|
CA2905496A1
(en)
|
2013-03-14 |
2014-09-25 |
Forsight Vision4, Inc. |
Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
|
US10517759B2
(en)
|
2013-03-15 |
2019-12-31 |
Glaukos Corporation |
Glaucoma stent and methods thereof for glaucoma treatment
|
EP3981388A1
(en)
|
2013-03-21 |
2022-04-13 |
Eupraxia Pharmaceuticals USA LLC |
Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
|
AU2014241163B2
(en)
|
2013-03-28 |
2018-09-27 |
Forsight Vision4, Inc. |
Ophthalmic implant for delivering therapeutic substances
|
JP6340673B2
(en)
|
2013-05-02 |
2018-06-13 |
レティナ ファウンデーション オブ ザ サウスウエストRetina Foundation Of The Southwest |
Double-layered ocular implant
|
US20160355573A1
(en)
|
2013-09-05 |
2016-12-08 |
Cornell University |
Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
|
US10087224B2
(en)
|
2013-11-01 |
2018-10-02 |
Cornell University |
Gene therapy for Alzheimer's and other neurodegenerative diseases and conditions
|
AU2014369834B2
(en)
|
2013-12-24 |
2018-12-20 |
President And Fellows Of Harvard College |
Cortistatin analogues and syntheses and uses thereof
|
WO2015112739A1
(en)
|
2014-01-22 |
2015-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds and method for treating parp1-deficient cancers
|
ES2948036T3
(en)
|
2014-02-18 |
2023-08-30 |
Alcon Inc |
Apparatus for resection of an intraocular lens
|
WO2015184173A1
(en)
|
2014-05-29 |
2015-12-03 |
Dose Medical Corporation |
Implants with controlled drug delivery features and methods of using same
|
WO2016005599A1
(en)
|
2014-07-10 |
2016-01-14 |
Biocopea Limited |
Compositions, methods and uses for treating gender-biased immune disorders
|
WO2016011191A1
(en)
|
2014-07-15 |
2016-01-21 |
Forsight Vision4, Inc. |
Ocular implant delivery device and method
|
SG11201700943TA
(en)
|
2014-08-08 |
2017-03-30 |
Forsight Vision4 Inc |
Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
|
US10507101B2
(en)
|
2014-10-13 |
2019-12-17 |
W. L. Gore & Associates, Inc. |
Valved conduit
|
CA2967330A1
(en)
|
2014-11-10 |
2016-05-19 |
Forsight Vision4, Inc. |
Expandable drug delivery devices and methods of use
|
AU2015380300B2
(en)
|
2015-01-30 |
2020-01-02 |
Alcon Inc. |
Modular intraocular lens designs
|
CA2982213C
(en)
|
2015-04-09 |
2022-10-18 |
Cornell University |
Gene therapy to prevent reactions to allergens
|
US20160296532A1
(en)
|
2015-04-13 |
2016-10-13 |
Forsight Vision5, Inc. |
Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
|
EP3294298A4
(en)
|
2015-05-08 |
2018-10-17 |
President and Fellows of Harvard College |
Cortistatin analogues, syntheses, and uses thereof
|
CA2985786A1
(en)
|
2015-05-12 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone
|
MX2017014966A
(en)
|
2015-05-28 |
2018-08-15 |
Univ Cornell |
Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema.
|
BR112017026103B1
(en)
|
2015-06-04 |
2023-10-03 |
Sol-Gel Technologies Ltd |
TOPICAL COMPOSITIONS WITH HEDGEHOG INHIBITOR COMPOUND, TOPICAL DELIVERY SYSTEM AND THEIR USES
|
US10669321B2
(en)
|
2015-06-08 |
2020-06-02 |
Retinal Solutions Llc |
Retinal capillary regeneration with synthetic norrin protein
|
US10202429B2
(en)
|
2015-06-08 |
2019-02-12 |
Retinal Solutions Llc |
Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema
|
US10206978B2
(en)
|
2015-06-08 |
2019-02-19 |
Retinal Solutions Llc |
Norrin regulation of junction proteins and the use thereof to treat epithelial or endothelial membrane leakage induced edema
|
EP3316889A4
(en)
|
2015-07-01 |
2018-11-14 |
President and Fellows of Harvard College |
Cortistatin analogues and syntheses and uses thereof
|
WO2017040853A1
(en)
|
2015-09-02 |
2017-03-09 |
Glaukos Corporation |
Drug delivery implants with bi-directional delivery capacity
|
US11564833B2
(en)
|
2015-09-25 |
2023-01-31 |
Glaukos Corporation |
Punctal implants with controlled drug delivery features and methods of using same
|
PT3206672T
(en)
|
2015-10-27 |
2018-06-20 |
Eupraxia Pharmaceuticals Inc |
Sustained release formulations of local anesthetics
|
JP6823071B2
(en)
|
2015-10-31 |
2021-01-27 |
アイオー セラピューティクス インコーポレイテッド |
Treatment of nervous system disorders with a combination of RXR agonists and thyroid hormones
|
JP6993328B2
(en)
|
2015-11-04 |
2022-01-13 |
クラービスタ メディカル,インコーポレイテッド |
Modular intraocular lens system
|
US11180538B2
(en)
|
2015-11-13 |
2021-11-23 |
University Of Utah Research Foundation |
Combinatorial gene construct and non-viral delivery for anti-obesity
|
CN113069681B
(en)
|
2015-11-20 |
2022-12-23 |
弗赛特影像4股份有限公司 |
Method of manufacturing a therapeutic device for sustained drug delivery
|
CA3014774A1
(en)
|
2016-02-17 |
2017-08-24 |
Children's Medical Center Corporation |
Ffa1 (gpr40) as a therapeutic target for neural angiogenesis diseases or disorders
|
KR20180121983A
(en)
|
2016-03-10 |
2018-11-09 |
아이오 테라퓨틱스, 인크. |
Treatment of muscle disorders using a combination of RXR agonists and thyroid hormones
|
US10946001B2
(en)
|
2016-03-10 |
2021-03-16 |
Io Therapeutics, Inc. |
Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
|
ES2837524T3
(en)
|
2016-04-05 |
2021-06-30 |
Forsight Vision4 Inc |
Implantable ocular drug delivery devices
|
WO2017184881A1
(en)
|
2016-04-20 |
2017-10-26 |
Harold Alexander Heitzmann |
Bioresorbable ocular drug delivery device
|
US10501744B2
(en)
|
2016-05-04 |
2019-12-10 |
Indiana University Research And Technology Corporation |
Presentation of bioactive proteins
|
US11045309B2
(en)
|
2016-05-05 |
2021-06-29 |
The Regents Of The University Of Colorado |
Intraocular lens designs for improved stability
|
USD844795S1
(en)
|
2016-11-30 |
2019-04-02 |
Bruder Healthcare Company, Llc |
Therapeutic eye mask
|
USD871598S1
(en)
|
2016-11-30 |
2019-12-31 |
Bruder Healthcare Company, Llc |
Therapeutic eye mask
|
US11406533B2
(en)
|
2017-03-17 |
2022-08-09 |
W. L. Gore & Associates, Inc. |
Integrated aqueous shunt for glaucoma treatment
|
EP3634438A4
(en)
|
2017-06-05 |
2021-03-03 |
The Regents of The University of California |
Compositions for treating retinal diseases and methods for making and using them
|
US11382736B2
(en)
|
2017-06-27 |
2022-07-12 |
Alcon Inc. |
Injector, intraocular lens system, and related methods
|
US11103460B2
(en)
|
2017-08-07 |
2021-08-31 |
Board Of Regents, The University Of Texas System |
Fabrication methods for nanodelivery systems for long term controlled delivery of active pharmaceutical ingredients
|
AU2018335393A1
(en)
|
2017-09-20 |
2020-04-02 |
Io Therapeutics, Inc. |
Treatment of disease with esters of selective RXR agonists
|
BR112020006601A2
(en)
|
2017-10-02 |
2020-12-08 |
Genedit Inc. |
RNA MODIFIED CPF1 GUIDE
|
WO2019079572A1
(en)
|
2017-10-18 |
2019-04-25 |
Washington University |
Dominant negative sarm1 molecules as a therapeutic strategy for neurodegenerative diseases or disorders
|
CN111655206B
(en)
|
2017-11-21 |
2022-10-14 |
弗赛特影像4股份有限公司 |
Fluid exchange device for expandable port delivery system and method of use
|
BR112020012830A2
(en)
|
2017-12-29 |
2021-01-26 |
Cornell University |
gene therapy for eosinophilic disorders
|
AU2019249162A1
(en)
|
2018-04-03 |
2020-11-26 |
Cornell University |
Gene therapy for oxidative stress
|
WO2019222121A1
(en)
*
|
2018-05-12 |
2019-11-21 |
Goldenbiotech, Llc |
Self-retaining implantable drug delivery device
|
US11821009B2
(en)
|
2018-05-15 |
2023-11-21 |
Cornell University |
Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
|
US11690806B2
(en)
|
2018-05-24 |
2023-07-04 |
Celanese Eva Performance Polymers Llc |
Implantable device for sustained release of a macromolecular drug compound
|
BR112020023983A2
(en)
|
2018-05-24 |
2021-02-23 |
Celanese Eva Performance Polymers Llc |
implantable device for prolonged release of a macromolecular drug compound
|
CA3108324A1
(en)
|
2018-07-31 |
2020-02-06 |
Cornell University |
Gene therapy methods to control organ function
|
US11628466B2
(en)
|
2018-11-29 |
2023-04-18 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
US11678983B2
(en)
|
2018-12-12 |
2023-06-20 |
W. L. Gore & Associates, Inc. |
Implantable component with socket
|
US11039954B2
(en)
|
2019-03-21 |
2021-06-22 |
Microoptx Inc. |
Implantable ocular drug delivery devices and methods
|
US11819590B2
(en)
|
2019-05-13 |
2023-11-21 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
US10966950B2
(en)
|
2019-06-11 |
2021-04-06 |
Io Therapeutics, Inc. |
Use of an RXR agonist in treating HER2+ cancers
|
KR20220036946A
(en)
|
2019-06-27 |
2022-03-23 |
레이어바이오 인크. |
Ocular Device Delivery Methods and Systems
|
EP4007609A1
(en)
|
2019-08-01 |
2022-06-08 |
Cornell University |
Targeted gene therapy to treat neurological diseases
|
WO2021076794A1
(en)
|
2019-10-15 |
2021-04-22 |
Cornell University |
Methods for modulating level of expression from gene therapy expression cassette
|
KR20220082050A
(en)
|
2019-10-16 |
2022-06-16 |
코넬 유니버시티 |
Gene therapy for Alzheimer's disease
|
US20230001017A1
(en)
|
2019-10-28 |
2023-01-05 |
University Of Lowa Research Foundation |
Formulation for delivery of lubricin gene
|
US20230044351A1
(en)
|
2019-11-25 |
2023-02-09 |
Cornell University |
Apoe gene therapy
|
EP4118202A1
(en)
|
2020-03-20 |
2023-01-18 |
Athanor Biosciences, Inc. |
Bacteriophage-based vaccines and engineered bacteriophage
|
CA3179541A1
(en)
|
2020-04-05 |
2021-10-14 |
Athanor Biosciences, Inc. |
Bacteriophage-based antibodies and protein-based binders
|
JP2023523931A
(en)
|
2020-04-23 |
2023-06-08 |
ユニヴァーシティ オブ アイオワ リサーチ ファウンデーション |
GPER proteolytic targeting chimera
|
EP4157309A1
(en)
|
2020-06-01 |
2023-04-05 |
Black Cat Bio Limited |
Compositions and methods for treating infections and netopathy
|
US20230374483A1
(en)
|
2020-07-08 |
2023-11-23 |
Regents Of The University Of Minnesota |
Modified hexosaminidase and uses thereof
|
WO2022036104A1
(en)
|
2020-08-12 |
2022-02-17 |
University Of Iowa Research Foundation |
Insulin sensitizers for the treatment of diabetes mellitus
|
US20230293678A1
(en)
|
2020-08-21 |
2023-09-21 |
Aliasger K. Salem |
Cationic nanoparticle adjuvants
|
US20230414787A1
(en)
|
2020-08-27 |
2023-12-28 |
University Of Iowa Research Foundation |
Gene knock-out for treatment of glaucoma
|
WO2022125963A1
(en)
|
2020-12-11 |
2022-06-16 |
University Of Iowa Research Foundation |
Compositions comprising molecules for cystic fibrosis treatment
|
EP4340894A1
(en)
|
2021-05-21 |
2024-03-27 |
University Of Iowa Research Foundation |
Anti-oxidant containing particles and methods of use
|
WO2023031277A1
(en)
|
2021-08-31 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of ocular rosacea
|
US11357620B1
(en)
|
2021-09-10 |
2022-06-14 |
California LASIK & Eye, Inc. |
Exchangeable optics and therapeutics
|
US11896558B2
(en)
|
2021-12-07 |
2024-02-13 |
Io Therapeutics, Inc. |
Use of an RXR agonist and taxanes in treating Her2+ cancers
|
WO2023130022A2
(en)
|
2021-12-29 |
2023-07-06 |
University Of Iowa Research Foundation |
Cystatin rna compositions for tissue engineering
|
WO2023164727A1
(en)
|
2022-02-28 |
2023-08-31 |
University Of Iowa Research Foundation |
A-fabp antibodies for diagnosis and treatment of obesity-associated diseases
|
US20230346862A1
(en)
|
2022-05-02 |
2023-11-02 |
Athanor Biosciences, Inc. |
Cancer eradicating - bio-nanoparticles (ce-bnp)
|
WO2023215560A1
(en)
|
2022-05-05 |
2023-11-09 |
Atoosa Corporation |
Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
|
WO2024037982A1
(en)
|
2022-08-16 |
2024-02-22 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical formulations of nintedanib for intraocular use
|